Core Viewpoint - The company, Guofang Co., Ltd. (600538.SH), provided a response to the Shanghai Stock Exchange regarding its 2025 performance forecast, addressing concerns about revenue composition, growth in the pharmaceutical distribution business, and significant goodwill impairment [1] Group 1: Revenue and Performance - The company expects a revenue of approximately 330 million yuan for 2025, with a net revenue of 327.2 million yuan after deducting unrelated income of 2.4808 million yuan [1] - The pharmaceutical distribution business accounts for nearly 58% of total revenue, showing a year-on-year growth of 4.43%, while the judicial IVD and pharmaceutical manufacturing segments experienced declines of 10% and 23.44%, respectively [1] - The top five customers in the pharmaceutical distribution sector remain stable, while the judicial IVD sector has seen significant fluctuations due to intensified bidding competition [1] Group 2: Growth Justification - The company attributes the growth in the pharmaceutical distribution business primarily to increased sales to hospitals, particularly in collective procurement varieties and narcotic drugs [1] - The delivery method is mainly through home delivery or express services, with revenue recognized upon customer signature, aligning the 4.43% growth rate with the pharmaceutical market growth of approximately 4%-4.5% in the Beibu Gulf region [1] Group 3: Goodwill Impairment - The company disclosed that its subsidiary, Gaosheng Bio, has underperformed due to reduced budgets from public security clients and intense market competition, leading to significant goodwill impairment [1] - Following impairments of approximately 55 million yuan and 60 million yuan in 2023 and 2024, respectively, the company plans to recognize an additional impairment of about 62 million yuan in 2025 [1] - A sensitivity analysis indicates that further declines in revenue or gross margin for Gaosheng Bio may necessitate additional impairment, which could significantly impact the company's profits [1]

Core Viewpoint - The company, Beihai Guofa Chuanshan Biological Co., Ltd., is responding to an inquiry from the Shanghai Stock Exchange regarding its 2025 performance forecast, which includes an expected revenue of approximately 330 million yuan and a net loss of 85 million yuan [2][3]. Financial Data Summary - The company is currently preparing its 2025 annual report, and the disclosed financial data is preliminary and unaudited, subject to adjustments [2]. - The expected revenue for 2025 is approximately 330 million yuan, with a net profit attributable to the parent company projected at -85 million yuan [2][3]. Revenue Breakdown by Business Segment - **Pharmaceutical Distribution**: Expected revenue growth of 4.43% compared to the previous year, driven by increased sales from centralized procurement and narcotic drugs [4][5]. - **Pharmaceutical Manufacturing**: Anticipated revenue decline of 23.44%, primarily due to maintenance affecting production capacity and sales policy optimization [6]. - **Judicial IVD Business**: Expected revenue decrease of 10.00%, attributed to reduced executable orders and intensified market competition [7]. - **Other Businesses**: Projected revenue growth of 32.74%, mainly due to a low base from the previous year and slight increases in consulting service income [8]. Major Clients and Changes - **Pharmaceutical Distribution**: The top five clients remain stable, with no significant changes in the client base from 2024 to 2025 [9][10]. - **Pharmaceutical Manufacturing**: The top five clients are consistent, with minor fluctuations in purchasing amounts due to adjustments in sales policies [11][12]. - **Judicial IVD Business**: Significant changes in the top five clients due to increased market competition and unsuccessful bids for government contracts [14]. Revenue Recognition Policies - The company maintains consistent revenue recognition policies, with no changes in accounting practices for 2025 [16][17]. - Revenue is recognized when control of the product is transferred to the customer, with specific criteria for direct sales and third-party shipments [28][30]. Market and Industry Analysis - The pharmaceutical distribution market in the North Bay area is expected to grow by approximately 4.0%-4.5% in 2025, influenced by healthcare infrastructure expansion and seasonal public health events [32][33]. - The impact of centralized procurement policies is expected to suppress revenue growth by approximately 1.0-1.5 percentage points due to price reductions [33]. - The company’s revenue growth aligns with industry trends, as comparable companies in the region show varied performance, with growth rates ranging from -1.47% to 5.2% [35].

Core Viewpoint - The company has released a special announcement regarding its performance forecast for 2025, indicating expected revenue of approximately 330 million yuan and a net loss attributable to the parent company of 85 million yuan, along with a planned goodwill impairment provision of about 62.45 million yuan [1]. Group 1: Revenue and Profitability - The company expects to achieve an operating revenue of 329.56 million yuan for 2025, with a net profit of -8.5 million yuan after deducting unrelated business income [1]. - The pharmaceutical distribution business is projected to generate 190.72 million yuan in revenue, accounting for 57.87% of total revenue, with a year-on-year growth of 4.43% [2]. - The revenue from the pharmaceutical distribution business is primarily driven by increased sales from centralized procurement and narcotic drugs, with centralized procurement revenue growing by 56% to 17.33 million yuan [2]. Group 2: Business Segment Performance - The pharmaceutical manufacturing segment is expected to generate 27.14 million yuan, reflecting a year-on-year decline of 23.44% due to maintenance of the eye drop production line and sales policy optimization [3]. - The IVD business is projected to generate 106.85 million yuan, down 10% year-on-year due to reduced executable orders and intensified market competition [3]. - Other business revenues increased by 32.74% to 4.84 million yuan, mainly driven by growth in consulting service fees [3]. Group 3: Market Context and Comparisons - The growth in the pharmaceutical distribution business aligns with regional market demand and industry trends, with the total drug sales in the Beibu Gulf region expected to grow by 4.0%-4.5% in 2025 [4]. - The company’s revenue growth rate is in line with comparable companies in the industry, such as Jiuzhoutong and Sinopharm, which reported revenue growth rates of 5.2% and 3.56% respectively [4]. - The distribution of revenue across quarters is balanced, with no significant concentration of revenue recognition at the end of the period [4]. Group 4: Goodwill Impairment - The company plans to recognize a goodwill impairment of 62.45 million yuan due to ongoing performance pressure from the acquisition of Guangzhou Gaoshen Biotechnology Co., which has seen a decline in revenue and profit since 2023 [5]. - The revenue realization rate for the acquired business is only 42.25%, with net profit realization at -2.39%, attributed to budget cuts from police clients and increased market competition [5]. - The company has previously recognized goodwill impairments of 55 million yuan and 60 million yuan in 2023 and 2024, respectively, with a remaining goodwill balance of 138 million yuan by the end of 2024 [5].

目 录 | 关于营业收入………………………………………………… 一、 | 第 1—11 | 页 | | --- | --- | --- | | 二、关于医药流通业务……………………………………………第 | 11—19 | 页 | | 三、关于商誉减值…………………………………………………第 | 19—32 | 页 | 问询函专项说明 天健函〔2026〕2-29 号 上海证券交易所： 由北海国发川山生物股份有限公司（以下简称公司）转来的《关于北海国发 川山生物股份有限公司业绩预告相关事项的问询函》（上证公函〔2026〕0106 号，以下简称问询函）奉悉。我们已对问询函中需要我们说明的财务事项进行了 审慎核查，现汇报说明如下。 由于 2025 年年度财务报表的审计工作尚未完成，本说明中的 2025 年财务数 据均未经审计。本说明中部分合计数与各项目直接相加之和可能存在尾数差异， 这些差异是由四舍五入造成的,除特别注明外，所涉及金额单位均为万元。 一、关于营业收入 第 1 页 共 32 页 · 交易，如存在，请详细说明相关情况及其商业实质。请年审会计师对前述问题发 表明确意见。（问询函第 1 条） (一) 根据《上 ...

证券代码：600538 证券简称：国发股份 公告编号：临 2026-005 北海国发川山生物股份有限公司 关于上海证券交易所对公司业绩预告相关事项 问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 截至本回复公告之日，公司 2025 年度年报编制工作尚在进行中，本回复中 所披露的公司 2025 年度相关财务数据均为未经审计的初步测算数据，后续存在 财务数据调整的可能，具体准确的财务数据以公司后续正式披露的经审计 2025 年年报为准。 北海国发川山生物股份有限公司（以下简称"公司""国发股份"）于 2026 年 1 月 23 日收到了上海证券交易所上市公司监管一部《关于北海国发川山生物 股份有限公司业绩预告相关事项的问询函》（上证公函【2026】0106 号）（以下 简称"问询函"），公司及相关方对《问询函》提到的问题进行了认真讨论和研 究，现将《问询函》所涉及问题的回复公告如下： 一、公司对相关问题的回复 问题一： | 项 目 | 金额 | 相关业务开展情况及扣 | 是否存在其他应当扣 | | ...

最近业绩情况 公司1月16日发布的2025年业绩预告显示预计亏损8500万元，但亏损同比收窄10%，主要因子公司商誉 减值(约6200万元)及业务调整影响。市场对此前跌停反应过度，后续情绪有所缓和。 资金走向 经济观察网国发股份（600538）在2026年2月13日出现逆市上涨，主要受技术面超跌反弹、医药板块情 绪回暖、业绩利空阶段性消化及资金流向变化等因素影响。 股票近期走势 2月9日公司股价因业绩预亏及龙虎榜资金大幅流出跌停(单日跌幅10.05%)，随后连续两个交易日缩量震 荡。截至2月13日，股价短期技术指标进入超卖区间(KDJ的J值降至0.89)，存在修复需求。当日股价低 开高走，收盘报6.75元，涨幅4.81%，收复5日均线(6.614元)，但仍低于20日均线(7.016元)。 行业板块情况 尽管当日上证指数下跌1.26%，医药生物板块跌幅0.78%，但国发股份所属的医药商业板块跌幅收窄至 0.89%，部分资金流向小市值超跌股。公司流通市值仅35.38亿元，易受短期资金扰动。 2月13日主力资金小幅净流入15.19万元，与前一日净流出314.11万元相比呈现回流迹象。但整体成交额 仅1.40亿元，较 ...

Quantitative Factors and Construction Methods - **Factor Name**: Large Order Transaction Amount Ratio **Factor Construction Idea**: This factor captures the buying behavior of large capital by analyzing the proportion of large order transaction amounts in the total daily transaction amount[8] **Factor Construction Process**: 1. Use tick-by-tick transaction data to identify buy and sell orders based on the sequence numbers of bids and asks 2. Filter transactions by order size to identify large orders 3. Calculate the proportion of large buy order transaction amounts in the total daily transaction amount **Formula**: $ \text{Large Order Transaction Amount Ratio} = \frac{\text{Large Buy Order Transaction Amount}}{\text{Total Daily Transaction Amount}} $ **Evaluation**: This factor effectively reflects the buying behavior of large capital[8] - **Factor Name**: Net Active Buy Transaction Amount Ratio **Factor Construction Idea**: This factor measures the active buying behavior of investors by calculating the net active buy transaction amount as a proportion of the total daily transaction amount[8] **Factor Construction Process**: 1. Use tick-by-tick transaction data to classify each transaction as either active buy or active sell based on the buy/sell indicator 2. Subtract the active sell transaction amount from the active buy transaction amount to obtain the net active buy transaction amount 3. Calculate the proportion of the net active buy transaction amount in the total daily transaction amount **Formula**: $ \text{Net Active Buy Transaction Amount Ratio} = \frac{\text{Active Buy Transaction Amount} - \text{Active Sell Transaction Amount}}{\text{Total Daily Transaction Amount}} $ **Evaluation**: This factor provides insights into the active buying tendencies of investors[8] --- Factor Backtesting Results - **Large Order Transaction Amount Ratio**: - Top 10 stocks with the highest 5-day average values: 1. Hanjiang Heshan (603616.SH): 93.5%, 99.2% time-series percentile[10] 2. Minbao Optoelectronics (301362.SZ): 89.7%, 98.4% time-series percentile[10] 3. Hangdian Co., Ltd. (603618.SH): 86.1%, 99.6% time-series percentile[10] 4. Jinzhengda (002470.SZ): 85.2%, 83.9% time-series percentile[10] 5. Guofa Co., Ltd. (600538.SH): 84.9%, 92.4% time-series percentile[10] 6. Shunna Co., Ltd. (000533.SZ): 84.7%, 100.0% time-series percentile[10] 7. Quanzhu Co., Ltd. (603030.SH): 84.6%, 94.4% time-series percentile[10] 8. Beijing Investment Development (600683.SH): 84.5%, 96.0% time-series percentile[10] 9. Chongqing Steel (601005.SH): 84.3%, 52.2% time-series percentile[10] 10. Huadian International (600027.SH): 83.6%, 95.2% time-series percentile[10] - **Net Active Buy Transaction Amount Ratio**: - Top 10 stocks with the highest 5-day average values: 1. Minsheng Bank (600016.SH): 21.1%, 100.0% time-series percentile[11] 2. Kairuide (002072.SZ): 20.3%, 99.6% time-series percentile[11] 3. Intercontinental Oil & Gas (600759.SH): 19.5%, 100.0% time-series percentile[11] 4. Boen Group (001366.SZ): 17.8%, 100.0% time-series percentile[11] 5. Bowan Technology (600883.SH): 17.5%, 99.6% time-series percentile[11] 6. Xiangyou Technology (600476.SH): 16.8%, 99.2% time-series percentile[11] 7. Zhejiang Commercial Bank (601916.SH): 16.8%, 94.4% time-series percentile[11] 8. General Elevator (300931.SZ): 15.9%, 100.0% time-series percentile[11] 9. Weier Pharmaceutical (603351.SH): 15.3%, 94.0% time-series percentile[11] 10. Ruierte (002790.SZ): 15.2%, 98.4% time-series percentile[11]

Core Viewpoint - The pharmaceutical commercial sector experienced a slight increase of 0.39% on January 19, with significant contributions from stocks like Dajia Weikang, which led the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4114.0, up by 0.29%, while the Shenzhen Component Index closed at 14294.05, up by 0.09% [1] - Dajia Weikang (301126) led the sector with a closing price of 13.91, reflecting a rise of 6.43% and a trading volume of 162,500 shares, amounting to a transaction value of 220 million yuan [1] - Other notable performers included Dacianlin (603233) with a 4.37% increase, Guofang Co. (600538) up by 3.27%, and Yifeng Pharmacy (603939) rising by 2.55% [1] Group 2: Fund Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 436 million yuan from institutional investors, while retail investors contributed a net inflow of 486 million yuan [2] - The individual stock fund flow indicated that Ruikang Pharmaceutical (002589) had a net inflow of 19.77 million yuan from institutional investors, while it faced a net outflow of 17.52 million yuan from retail investors [3] - Dajia Weikang (301126) also experienced a net inflow of 13.40 million yuan from institutional investors, despite a net outflow of 15.06 million yuan from retail investors [3]

Core Viewpoint - The company Guofang Co., Ltd. (stock code: 600538.SH) expects a net loss of approximately 85 million yuan for the fiscal year 2025, which represents a reduction in loss of about 9 million yuan compared to the previous year, indicating a year-on-year decrease in loss of 10% [1] Financial Performance - The projected net loss for 2025 is around 85 million yuan [1] - The expected loss reduction compared to the previous year is approximately 9 million yuan [1] - The year-on-year percentage decrease in loss is 10% [1]

Revenue Projections - The company expects to achieve approximately CNY 330 million in revenue for the fiscal year 2025, with no significant unrelated business income included [3]. - In 2024, the company reported revenue of CNY 340.46 million and a net loss of CNY -93.85 million [5]. - The decline in revenue is primarily due to intensified market competition, leading to a 10% decrease in revenue and a 3% drop in gross margin for the wholly-owned subsidiary Guangzhou Gaosheng Biotechnology Co., Ltd. [6]. - The pharmaceutical plant of Beihai Guofa Chuanshan Bio Co., Ltd. experienced a 30% decline in revenue due to maintenance of the eye drop production line and delays in sales recovery [6]. Net Loss Projections - The projected net loss attributable to the parent company for 2025 is around CNY -85 million, representing a decrease in loss of approximately CNY 9 million or 10% compared to the previous year [4]. - The net loss attributable to the parent company, after excluding non-recurring gains and losses, is expected to be around CNY -85.5 million, a reduction of approximately CNY 4.5 million compared to the previous year [4]. Goodwill Impairment - The company anticipates a goodwill impairment provision of approximately CNY 62 million due to the acquisition of Guangzhou Gaosheng Biotechnology Co., Ltd. [6]. Financial Reporting - The financial data provided is preliminary and has not been audited by a registered accountant, and the final figures will be disclosed in the audited annual report for 2025 [8].